登录 | 注册    关注公众号  
微信公众号
搜索
 > 【Osteoprotegerin】

Osteoprotegerin信息

英文名称:Tumor necrosis factor ligand superfamily member 11
中文名称:肿瘤坏死因子配体超家族成员11
靶点别称:Osteoclast differentiation factor,TRANCE,TNFSF11,TNF-related activation-induced cytokine,Tumor necrosis factor ligand superfamily member 11,CD254,TNF Superfamily Member 11,Osteoprotegerin Ligand,Receptor Activator Of Nuclear Factor Kappa B Ligand,Tumor Necrosis Factor Superfamily Member 11,ODF,RANKL,OPGL,CD254 Antigen,HRANKL2,TNLG6B,OPTB2,SOdf,RANK Ligand,Tumor Necrosis Factor (Ligand) Superfamily, Member 11,Receptor Activator Of Nuclear Factor Kappa-B Ligand,Tumor Necrosis Factor Ligand 6B
上市药物数量:7
临床药物数量:27
最高研发阶段:批准上市

Osteoprotegerin产品列表

产品库
物种
属性
ACRO质量管理体系
 
评论(0)
 

Osteoprotegerin分子别名

TNFRSF11B,OCIF,OPG,Osteoprotegerin

Osteoprotegerin分子背景

Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B) is also known as Osteoclastogenesis inhibitory factor (OCIF), Osteoprotegerin (OPG). TNFRSF11B is a secreted homodimer protein, which can interact with TNFSF10 and TNFSF11. TNFRSF11B acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. TNFRSF11B inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.

Osteoprotegerin上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验

Osteoprotegerin临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验

消息提示

请输入您的联系方式,再点击提交!

确定